Pulse Biosciences, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDPulse Biosciences, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 90), indicating clear outperformance against the broad market. Earnings contraction of 4% provides fundamental context to the price action. Investors should exercise caution due to high volatility (86% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $25.67 | +10.84% | ABOVE |
| 50 SMA | $24.03 | +18.39% | ABOVE |
| 100 SMA | $22.32 | +27.44% | ABOVE |
| 150 SMA | $19.55 | +45.50% | ABOVE |
| 200 SMA | $18.91 | +50.46% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PLSE in an uptrend right now?
PLSE has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, PLSE is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is PLSE overbought or oversold?
PLSE's RSI (14) is 60. The stock is in neutral territory, neither overbought nor oversold.
Is PLSE outperforming the market?
PLSE has a Relative Strength (RS) Rating of 90 out of 99. Yes, PLSE is a market leader, outperforming 90% of all stocks over the past 12 months.
Where is PLSE in its 52-week range?
PLSE is trading at $28.45, which is 92% of its 52-week high ($30.99) and 86% above its 52-week low ($12.56).
How volatile is PLSE?
PLSE has a Beta of 2.30 and 52-week volatility of 86%. It's more volatile than the S&P 500 - expect bigger swings.